369-06-012 ISMRM Abstract

A Dual Input Synthetic Tumor Generation Pipeline for Liver Lung Shunt Fraction Estimation

Primary: Body - Liver

Secondary: Interventional - MR-Guided Interventions

369-06-012 · Advances in Interventional MRI: Guidance, Motion Management, and Precision Treatment Technologies · Monday, 11 May, 5:05 PM–6:00 PM · Digital Posters Row J

Keywords: Hepatocellular carcinoma Dynamic contrast enhanced MRI Lung Shunt Fraction Quantitative Transport Mapping Noninvasive Estimation

Accepted

Dominick Romano^1,2, Benjamin Weppner^1,2, Qihao Zhang¹, Renjiu Hu^1,3, Alexandra G Roberts^1,4, Maneesh John^1,4, Kyungmouk Steve Lee¹, Adam D Talenfeld¹, martin r R prince^1,5, Pascal Spincemaille ⁶, Yi Wang ^1,2

¹Radiology, Weill Cornell Medicine, New York, United States of America

²Biomedical Engineering, Cornell University, Ithaca, United States of America

³Mechanical & Aerospace Engineering, Cornell University, Ithaca, United States of America

⁴Electrical & Computer Engineering, Cornell University, Ithaca, United States of America

⁵Columbia University Vagelos College of Physicians and Surgeons, New York, United States of America

⁶Weill Cornell Medicine, New York, United States of America

Presenting Author: Yi Wang

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Oh JH, Jun DW. The latest global burden of liver cancer: A past and present threat. Clin Mol Hepatol. Apr 2023;29(2):355-357. doi:10.3350/cmh.2023.0070 [doi]

2. Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol. Mar 14 2023;29(10):1551-1568. doi:10.3748/wjg.v29.i10.1551 [doi]

3. Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol. Mar 28 2018;6(1):69-78. doi:10.14218/jcth.2017.00031 [doi]

4. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology. Oct 2018;68(4):1429-1440. doi:10.1002/hep.29691 [doi]

5. Zhang Q. Estimating Perfusion and Vascular Properties from Medical Images: Quantitative Transport Mapping (QTM). Ph.D. Cornell University; 2023. https://www.proquest.com/dissertations-theses/estimating-perfusion-vascular-properties-medical/docview/2827576793/se-2?accountid=10267

6. Zöllner F, Lietzmann F, Attenberger U, Haneder S, Michaely H, Schad L. Data from: DCE-MRI of the human kidney using BLADE: A feasibility study in healthy volunteers [Dataset]. 2019;V1. Deposited 2019-02-06 13:37:53.363. doi:doi:10.11588/DATA/5RSAM3 [doi]

7. Lietzmann F, Zöllner FG, Attenberger UI, Haneder S, Michaely HJ, Schad LR. DCE-MRI of the human kidney using BLADE: A feasibility study in healthy volunteers. Journal of Magnetic Resonance Imaging. 2012;35(4):868-874. doi:https://doi.org/10.1002/jmri.23509 [doi]

8. Sourbron SP, Buckley DL. On the scope and interpretation of the Tofts models for DCE-MRI. Magnetic Resonance in Medicine. 2011;66(3):735-745. doi:https://doi.org/10.1002/mrm.22861 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/369-06-012